Articles Vol. 67 No. Số CĐ12- Bệnh viện Ung bướu Nghệ An (2026) 14/08/2026

EFFICACY OF ADJUVANT CHEMOTHERAPY WITH OXALIPLATIN AND 5-FLUOROURACIL IN STAGE II-III GASTRIC CANCER PATIENTS AT THANH HOA ONCOLOGY HOSPITAL

Nguyen Thi Trang1,2, Vu Thi Hang3,4, Le Thi Lan Huong5,6
1 MSc, MD, Department of Internal Medicine 1 – Oncology Hospital
2 ThS. BS khoa Nội 1 - Bệnh viện UBTH
3 MSc, Specialist Level II Doctor – Head of Internal Medicine Department 1, UBTH Hospital
4 ThS.BSCKII. Trưởng khoa Nội 1 - Bệnh viện UBTH
5 Physician, Department of Internal Medicine 1 – UBTH Hospital
6 BS. Khoa Nội 1 – Bệnh viện UBTH
DOI: 10.52163/yhc.v67iCD12.6139
642 Views
0 Downloads
Keywords
Stage II–III gastric cancer; Adjuvant chemotherapy; Oxaliplatin – 5FU.
Abstract

Objective: To evaluate the outcomes and adverse effects of the adjuvant Oxaliplatin – 5FU regimen in stage II–III gastric cancer patients at Thanh Hoa Oncology Hospital. Patients and Methods: A retrospective descriptive study was conducted on 45 patients with stage II–III gastric cancer who underwent radical surgery followed by adjuvant Oxaliplatin – 5FU chemotherapy from January 2022 to August 2025 at Thanh Hoa Oncology Hospital. Results: The mean study period was 23 ± 7.89 months. The 3-year overall survival (OS) rate was 73.1%, with a mean overall survival time of 34.63 ± 1.47 months. The 3-year disease-free survival (DFS) rate was 54.7%, with a mean disease-free survival time of 30.87 ± 1.80 months. Adverse effects were predominantly grades 1–2. Conclusion: The adjuvant Oxaliplatin – 5FU regimen for stage II–III gastric cancer at Thanh Hoa Oncology Hospital is safe and effective.

References
[1]
Đỗ Thị Hằng. Kết quả điều trị bổ trợ bệnh nhân ung thư dạ dàygiai đoạn II, III bằng phác đồ XELOX tại BVĐK tỉnh Vĩnh Phúc. Luận văn Thạc sỹ. Đại Học Y Hà Nội; 2023 Google Scholar
[2]
Lê Thị Thu Nga. Đánh giá kết quả điều trị hóa chất bổ trợ phác đồ XELOX sau phẫu thuật ung thư dạ dày, Luận Văn tiến sĩ. Đại Học Y Hà Nội; 2022. Google Scholar
[3]
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial - The Lancet. Accessed September 30, 2024. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61873-4/abstract Google Scholar
[4]
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine | New England Journal of Medicine. Accessed September 30, 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa072252 Google Scholar
[5]
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer | New England Journal of Medicine. Accessed September 30, 2024. https://www.nejm.org/doi/full/10.1056/nejmoa073149 Google Scholar
[6]
Cancer (IARC) TIA for R on. Global Cancer Observatory. Accessed September 22, 2024. https://gco.iarc.fr/ Google Scholar
[7]
Impact of Adjuvant FOLFOX on Quality of Life and Peripheral Neuropathy Incidence in Patients With Gastric Cancer: A Prospective Cohort Study. Value Health Reg Issues. 2023;35:13-18. doi:10.1016/j.vhri.2022.12.005 Google Scholar
[8]
Ke B, Song XN, Liu N, Zhang RP, Wang CL, Liang H. Prognostic value of the lymph node ratio in stage III gastric cancer patients undergoing radical resection. PloS One. 2014;9(5):e96455. doi:10.1371/journal.pone.0096455 Google Scholar
[9]
Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy | Gastric Cancer. Accessed September 30, 2024. https://link.springer.com/article/10.1007/s10120-015-0581-1 Google Scholar
[10]
Zhang XL, Shi HJ, Cui SZ, Tang YQ, Ba MC. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2011;37(6):466-472. doi:10.1016/j.ejso.2011.01.027 Google Scholar